News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘BreastCancer’ clear

  • Practice-changing clinical research conducted at the Dana-Farber Cancer Institute Department of Biostatistics and Computational Biology was featured at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session.

Tags: BreastCancer, ProstateCancer

  • Results from a study evaluating an oral daily dose of the drug enobosarm, shows promise for women with metastatic, androgen receptor positive, estrogen receptor positive breast cancer.

Tags: BreastCancer, TargetedTherapy

  • Ursula Matulonis, MD, and colleagues report a two-drug combination that disrupts critical signaling circuits in cancer cells has produced an observable benefit in patients with recurrent high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC).

Tags: BreastCancer, CervicalCancer

  • Erica Mayer, MD, MPH, and colleagues are leading a pilot phase 2 clinical trial to test the feasibility of the targeted drug palbociclib combined with endocrine therapy as adjuvant therapy for stage II and III breast cancer.

Tags: BreastCancer, TargetedTherapy

  • Researchers at Dana-Farber have developed a tool to help predict how a patient’s tumor is likely to behave and which of several possible treatments is most likely to be effective.

Tags: BreastCancer, Genetics

  • Cancer death rates in the United States continue to decline, according to the Annual Report to the Nation on the Status of Cancer, published online by the journal Cancer.

Tags: BreastCancer, ColonCancer, LungCancer, Prevention

  • In a nationwide study of women with triple-negative breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of patients whose tumors shrank away completely.

Tags: chemotherapy, BreastCancer

  • Women being treated with breast cancer drugs known as aromatase inhibitors can markedly ease the joint pain associated with the drugs by engaging in moderate daily exercise, Dana-Farber Cancer Institute and Yale University investigators report in a study to be presented during the San Antonio Breast Cancer Symposium.

Tags: BreastCancer, Exercise

  • In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment.

Tags: chemotherapy, BreastCancer, TargetedTherapy

  • Dana-Farber's Judy Garber, MD, MPH, an internationally recognized leader in clinical and translational research on breast cancer, has been elected to the Institute of Medicine.

Tags: BreastCancer, Honors, Genetics

Showing 1-10 of 46 items